glp 1/gip agonist Science Behind 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements The activity of GLP-1 and

We know that patients who are treated with GLP-1RA are much less likely to die from any cause than patients treated with DPP-IV inhibitors and sulfonylureas

Out of 175 different outcomes researchers included in the study, they found people who took GLP-1 medications had lower risks of 42 different health outcomes and higher risks for 19

This proved it to have fewer severe side effects in clinical trials and to cause less weight gain than other existing diabetics drugs

Li, D.-J

These variations significantly influence the role of GLP-1 in regulating islet function and glucose homeostasis

Progress and challenges in anti-obesity pharmacotherapy